secwatch.observer — SEC 8-K summary
======================================

Issuer:     Royalty Pharma plc (RPRX)
CIK:        0001802768
Form:       8-K
Filed at:   2025-12-22T23:59:59+00:00
Accession:  0001193125-25-328100
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Cytokinetics' MYQORZO; Royalty Pharma to receive 4.5% royalty on sales up to $5B
--------------------------------------------------------------------------------

- Royalty Pharma entitled to 4.5% royalty on MYQORZO sales up to $5B, decreasing to 1% above $5B.
- Long-term capital of $225M fully drawn; launch capital of $225M with $50M drawn to date.
- Royalty Pharma to receive $523M in quarterly repayments over 10 years (1.9x); $20M repaid through Sep 2025.
- Following approval, Cytokinetics can draw additional $175M within 12 months, repayable at 1.9x over 10 years.
- MYQORZO (aficamten) approved for symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802768/000119312525328100/0001193125-25-328100-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802768/000119312525328100/d35067d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-328100

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer